BIZENGRI (zenocutuzumab-zbco)
ANTINEOPLASTIC MONOCLONAL ANTIBODIES·NEUREGULIN 1 GENE FUSION POSITIVE PANCREATIC ADENOCARCINOMA·+2
SANOFI/PARTNER
Indication
Neuregulin 1 gene fusion positive non-small cell lung cancer
Neuregulin 1 gene fusion positive non-small cell lung cancer is a rare molecularly defined subset of primary thoracic epithelial malignancy, characterized by genomic rearrangements involving the *NRG1* gene. Read more about Neuregulin 1 gene fusion positive non-small cell lung cancer
1 drugs 1 manufacturers
Drugs that treat it
Common Neuregulin 1 gene fusion positive non-small cell lung cancer therapies.
Filter & compare in the drug finder →Opens the drug finder with Neuregulin 1 gene fusion positive non-small cell lung cancer preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonNeuregulin 1 gene fusion positive non-small cell lung cancer is a rare molecularly defined subset of primary thoracic epithelial malignancy, characterized by genomic rearrangements involving the *NRG1* gene.
Primarily affecting adults and strongly enriched in non-smoking individuals with invasive mucinous lung adenocarcinomas, this clinical entity arises within the respiratory system.
Pathophysiologically, the structural rearrangement preserves the epidermal growth factor-like domain of neuregulin-1, producing an aberrant chimeric ligand that constitutively binds and dimerizes ErbB3 (HER3) with ErbB2 (HER2).
This ligand-dependent receptor activation drives persistent downstream oncogenic signaling via the PI3K/AKT and MAPK pathways, promoting accelerated tumor proliferation, cell survival, and therapeutic resistance to conventional treatments.
- nih.gov
Neuregulin 1 gene fusion positive non-small cell lung cancer is a rare molecularly defined subset of primary thoracic epithelial malignancy, characterized by genomic rearrangements involving the *NRG1* gene
- nih.gov
Neuregulin 1 gene fusion positive non-small cell lung cancer is a rare molecularly defined subset of primary thoracic epithelial malignancy, characterized by genomic rearrangements involving the *NRG1* gene Pathophysiologically, the structural rearrangement preserves the epidermal growth factor-like domain of neuregulin-1, producing an aberrant chimeric ligand that constitutively binds and dimerizes ErbB3 (HER3) with ErbB2 (HER2)
- lung.org
Primarily affecting adults and strongly enriched in non-smoking individuals with invasive mucinous lung adenocarcinomas, this clinical entity arises within the respiratory system
- go2.org
Primarily affecting adults and strongly enriched in non-smoking individuals with invasive mucinous lung adenocarcinomas, this clinical entity arises within the respiratory system
- lungcancerresearchfoundation.org
This ligand-dependent receptor activation drives persistent downstream oncogenic signaling via the PI3K/AKT and MAPK pathways, promoting accelerated tumor proliferation, cell survival, and therapeutic resistance to conventional treatments
Personalize your experience
Follow Neuregulin 1 gene fusion positive non-small cell lung cancer and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.